stockportfolio.pro
Regeneron Pharmaceuticals, Inc. (REGN)
Healthcare · Biotechnology · NasdaqGS
Regeneron Pharmaceuticals, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.86B | $5.87B | $5.15B | $6.56B | $8.50B | $16.07B | $12.17B | $13.12B | $14.20B | $14.34B |
| Gross profit | $4.67B | $5.67B | $4.91B | $6.15B | — | — | — | — | — | — |
| Net income | $895.50M | $1.20B | $2.44B | $2.12B | $3.51B | $8.08B | $4.34B | $3.95B | $4.41B | $4.50B |
| Net margin | 18.4% | 20.4% | 47.5% | 32.3% | 41.3% | 50.2% | 35.6% | 30.1% | 31.1% | 31.4% |
Source: Regeneron Pharmaceuticals, Inc. SEC filings (10-K). 18 years of history available in the interactive view.
What growth is priced into REGN stock?
At today's market cap of $64.60B, Regeneron Pharmaceuticals, Inc. is priced for free-cash-flow growth of about 4.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $4.08B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 15.3%/yr over the last five fiscal years and revenue 11%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 18 years of Regeneron Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track REGN in your portfolio →
Regeneron Pharmaceuticals, Inc. financial history by metric
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Regeneron Pharmaceuticals, Inc. — frequently asked questions
What is Regeneron Pharmaceuticals, Inc.'s revenue?
Regeneron Pharmaceuticals, Inc. (REGN) reported revenue of $14.34B for fiscal year 2025, up 1.0% from the prior year, according to its SEC filings.
Is Regeneron Pharmaceuticals, Inc. profitable?
Yes. REGN earned net income of $4.50B in fiscal 2025, a net margin of 31.4%.
What is REGN's P/E ratio?
Regeneron Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 15.0 based on the latest data in our nightly-refreshed cache.
How fast is Regeneron Pharmaceuticals, Inc. growing?
REGN's revenue grew at roughly 11.0% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Regeneron Pharmaceuticals, Inc. have?
As of fiscal year 2025, REGN carried roughly $1.99B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Regeneron Pharmaceuticals, Inc.'s market cap?
Regeneron Pharmaceuticals, Inc. (REGN) has a market capitalization of about $64.60B, based on the latest data in our nightly-refreshed cache.
When does Regeneron Pharmaceuticals, Inc.'s fiscal year end?
REGN's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into REGN stock?
At today's market cap of $64.60B, Regeneron Pharmaceuticals, Inc. is priced for free-cash-flow growth of about 4.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $4.08B from the FY ending 2025-12-31). For comparison, free cash flow actually grew 15.3%/yr over the last five fiscal years and revenue 11%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Regeneron Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 18 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.